Vancouver, British Columbia–(Newsfile Corp. – May 30, 2024) – Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (“Numinus” or the “Company”) The company, a leader in mental health care and advancing evidence-based psychedelic medications, has unveiled a strategic blueprint aimed at strengthening its foothold across the United States.
Through comprehensive cost optimization initiatives, Numinus is poised to strengthen its already established network of wellness clinics and cutting-edge clinical research facilities across the U.S. At the same time, the company is stepping up efforts to increase awareness and participation in its practitioner training programs.
Central to this strategic vision is the rollout of a comprehensive membership program under the Numinus Network initiative that reinforces the company’s commitment to prioritizing scalable growth and maximizing shareholder returns.
“We are excited to enter our next phase of development, which will sharpen our focus on expanding access to psychedelic drug therapies and accelerate our path to monetization. We aim to empower the broader community of drug developers and healthcare providers by optimizing our therapeutic, research and training expertise. This strategic focus is to bring innovative therapies within reach of those who can benefit most,” said Payton Nyquvest, founder and CEO of Numinus.
As part of this initiative, Numinus has partnered with the Canadian Centre for Psychedelic Healing (Field Trip Health), known for its pioneering work in psychedelic treatment clinics in Canada. Therapists currently contracted with Numinus in Canada will have the opportunity to transition to Field Trip Health, and Numinus will earn a portion of revenue from patient referrals.
As part of this transition, Numinus clinics in Montreal, Toronto and Vancouver will close. Field Trip Health will take over the Montreal clinic and acquire certain assets from all three locations, strengthening its presence in the Canadian market. Meanwhile, Numinus will continue its research activities and lease space at Field Trip Health’s Vancouver clinic for certain clinical trials.
Numinus and Field Trip Health also entered into a dynamic three-year training and marketing agreement to collaborate on projects that advance the mutual interests of both companies. Field Trip Health will recommend Numinus’ psychedelic therapy trainings and develop content to be hosted on its learning portal. Numinus will recommend Field Trip Health clinics and receive referral fees from those who attend Field Trip Health. The companies will also collaborate on training, therapist recruitment and marketing campaigns for patient recruitment.
“We are eager to build a long-term strategic relationship with Numinus,” said Ian Ruberry, CEO of Field Trip Health. “Our clinicians actively seek top-level training and a safe, nurturing environment to optimize care for our clients. Working with Numinus ensures exactly that across our expanding network of clinics, ensuring the highest standards of service delivery.”
Former Canadian Numinus therapists and health professionals who transition into the Numinus network will continue to have access to cutting-edge treatment protocols, ongoing support and promotional opportunities within the Numinus community.
This collaboration with Field Trip Health will enable members of the Numinus network to access the medical infrastructure critical to the therapeutic administration of ketamine and other psychedelics within the Canadian regulatory framework. Upon completion of the pilot program, Numinus will launch and sell under a subscription-based model in Canada and the United States.
“As we transition from operating our Canadian clinics, we carefully selected companies that share our values of client safety and care,” Nikvest added. “We are grateful for the opportunity to work with the skilled and compassionate therapists, medical professionals and clinic staff to guide hundreds of patients on their mental health journeys. We look forward to continuing to support these services in Canada through our arrangements with Numinus Network and Field Trip Health.”
About Numinus
Numinus Wellness Inc. (TSX: NUMI) is dedicated to providing safe, evidence-based psychedelic-assisted therapies in mental health care. The company’s approach aims to heal, not just manage, symptoms of depression, anxiety, trauma, pain and substance use. Numinus is pioneering the integration of psychedelic-assisted therapies into mainstream clinical practice.
For more information, visit www.numinus.com and follow us on LinkedIn, Facebook and Instagram.
Numinous Wellness Co., Ltd.
Payton Nikvest
email address
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/210776
